Valeant Pharmaceuticals International (VRX) · page 21 of 39
The slide uses a 'villain' framing by contrasting the high penalties of established peers against the absence of the target company (Valeant).
Activist deck · preempt_rebuttal · preempt_rebuttal · dense density
Slide locked Sign in to view
Slide schematic 5/5
list 1/1 source-note 1/1 table 1/1 title 2/2
Components 5
bullet source-note data headline headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1